WD-3 improves anti-PD-L1 therapy by remodeling the tumor immune microenvironment through gut microbiota.
BACKGROUND: Gastric cancer (GC) ranks as the fifth most prevalent malignancy globally. CONCLUSION: Our data provide correlative evidence that WD-3 supplementation combined with alphaPD-L1 treatment may attenuate GC progress in the FMT mouse model, indicating association with the modulation of gut microbiota.
BACKGROUND: Gastric cancer (GC) ranks as the fifth most prevalent malignancy globally. CONCLUSION: Our data provide correlative evidence that WD-3 supplementation combined with alphaPD-L1 treatment may attenuate GC progress in the FMT mouse model, indicating association with the modulation of gut microbiota.
What the study was
- Study design
- Preclinical study
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Immunobiology
Why it surfaced
Low-signal Novel therapeutics: immunotherapy, CAR-T, targeted therapy entry (Preclinical study design); retained for topic coverage completeness.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.